US Pharma MarketingParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3
Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect. Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report…
Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect.
Source: FierceBiotech